$986 Million is the total value of BVF INC/IL's 43 reported holdings in Q1 2018. The portfolio turnover from Q4 2017 to Q1 2018 was 100.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| IRWD | New | IRONWOOD PHARMACEUTICALS INC | $85,519,000 | – | 5,542,400 | +100.0% | 8.67% | – |
| MRUS | New | MERUS N V | $44,832,000 | – | 2,419,443 | +100.0% | 4.54% | – |
| XNCR | New | XENCOR INC | $27,042,000 | – | 902,000 | +100.0% | 2.74% | – |
| PIRS | Buy | PIERIS PHARMACEUTICALS INC | $24,501,000 | +23.7% | 3,592,549 | +36.9% | 2.48% | +4.0% |
| CRVS | Buy | CORVUS PHARMACEUTICALS INC | $22,533,000 | +373.5% | 1,954,254 | +325.4% | 2.28% | +297.9% |
| RCUS | New | ARCUS BIOSCIENCES INC | $19,606,000 | – | 1,269,788 | +100.0% | 1.99% | – |
| SPRO | Buy | SPERO THERAPEUTICS INC | $14,948,000 | +23.6% | 1,048,958 | +1.9% | 1.52% | +3.9% |
| IMDZ | Buy | IMMUNE DESIGN CORP | $13,550,000 | +136.4% | 4,106,200 | +179.4% | 1.37% | +98.8% |
| SBPH | Buy | SPRING BK PHARMACEUTICALS INC | $12,800,000 | +15.6% | 832,247 | +1.1% | 1.30% | -2.8% |
| FWP | Buy | FORWARD PHARMA A/Ssponsored adr | $10,319,000 | -18.4% | 4,755,117 | +37.6% | 1.05% | -31.4% |
| VSTM | Buy | VERASTEM INC | $8,156,000 | +18.1% | 2,737,000 | +21.6% | 0.83% | -0.7% |
| ADRO | New | ADURO BIOTECH INC | $7,501,000 | – | 806,534 | +100.0% | 0.76% | – |
| ALBO | New | ALBIREO PHARMA INC | $7,328,000 | – | 225,000 | +100.0% | 0.74% | – |
| GNCA | New | GENOCEA BIOSCIENCES INC | $5,250,000 | – | 5,000,000 | +100.0% | 0.53% | – |
| PTGX | Buy | PROTAGONIST THERAPEUTICS INC | $3,484,000 | -43.1% | 405,600 | +37.9% | 0.35% | -52.2% |
| New | ESSA PHARMA INC | $1,935,000 | – | 10,183,646 | +100.0% | 0.20% | – |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2018-05-07
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| XENON PHARMACEUTICALS INC | 36 | Q3 2023 | 4.7% |
| PIERIS PHARMACEUTICALS INC | 30 | Q3 2023 | 2.8% |
| CYTOKINETICS INC | 29 | Q4 2020 | 11.8% |
| INFINITY PHARMACEUTICALS INC | 29 | Q2 2023 | 4.3% |
| XOMA CORP DEL | 28 | Q3 2023 | 7.3% |
| ARQULE INC | 27 | Q4 2019 | 4.8% |
| CHEMOCENTRYX INC | 26 | Q3 2019 | 13.8% |
| CYTOMX THERAPEUTICS INC | 26 | Q3 2023 | 5.3% |
| CORVUS PHARMACEUTICALS INC | 26 | Q3 2023 | 2.3% |
| ARRAY BIOPHARMA INC | 25 | Q2 2019 | 14.5% |
View BVF INC/IL's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 4 | 2024-06-18 |
| 4 | 2024-06-10 |
| 13F-HR | 2024-05-15 |
| 4 | 2024-05-13 |
| 13F-HR | 2024-02-14 |
| 4 | 2024-01-29 |
| 3 | 2024-01-26 |
| 4 | 2024-01-09 |
| 4 | 2023-12-20 |
| 4 | 2023-11-17 |
View BVF INC/IL's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.